Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
Vera Therapeutics, Inc. (VERA) will participate in the 44th Annual TD Cowen Health Care Conference. The company's management team will discuss IgAN and hold a Fireside Chat. Investors can access the webcast and a replay of the event on the company's website.
02/28/2024 - 04:20 PM
BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will participate in the 44th Annual TD Cowen Health Care Conference, which is taking place from March 4th to 6th at the Marriott Copley Place in Boston, MA.
IgAN Corporate Panel Discussion Details: Date: Monday, March 4th Time: 9:10 AM ET Vera Rep.: Robert Brenner, M.D., Chief Medical Officer Vera Therapeutics Fireside Chat Details: Date: Monday, March 4th Time: 2:10 PM ET Presenter: Marshall Fordyce, M.D., Chief Executive Officer Webcast: https://wsw.com/webcast/cowen154/vera/2016052
A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar ” section of the Vera Therapeutics website.
The management team will also participate in one-on-one investor meetings.
About Vera Therapeutics Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com .
For more information, please contact:
Investor Contact: Joyce Allaire LifeSci Advisors 212-915-2569jallaire@lifesciadvisors.com
Media Contact: Mari Purpura LifeSci Advisorsmpurpura@lifesciadvisors.com
The conference is from March 4th to 6th.
Robert Brenner, M.D., Chief Medical Officer of Vera Therapeutics.
Marshall Fordyce, M.D., Chief Executive Officer.
Investors can access the webcast at https://wsw.com/webcast/cowen154/vera/2016052.
The replay will be available for 90 days.
VERA Rankings
#4564 Ranked by Stock Gains
VERA Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About VERA
trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.